Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172268 | 0.77 | SLC1A3 (0.43) | OPRM1OPRD1TAAR1POLBALDH1A1 | |
| SCHEMBL7331954 | 0.76 | TAAR1 (0.54) | OPRM1OPRD1TAAR1KMT2APOLB | |
| SCHEMBL4461408 | 0.74 | OPRM1 (0.49) | OPRM1OPRD1TAAR1KMT2APOLB | |
| SCHEMBL3353073 | 0.73 | ALDH1A1 (0.53) | OPRM1OPRD1TAAR1KMT2AALDH1A1 | |
| SCHEMBL13870633 | 0.72 | GRM5 (0.48) | OPRM1OPRD1NPC1RAB9ATDP1 | |
| SCHEMBL8353449 | 0.72 | RAB9A (0.58) | KMT2APOLBALDH1A1NPC1RAB9A | |
| SCHEMBL599876 | 0.71 | KEAP1 (0.54) | OPRM1OPRD1TAAR1OPRK1DRD2 | |
| SCHEMBL12530212 | 0.70 | IAPP (0.50) | OPRM1OPRD1TAAR1KMT2AALDH1A1 | |
| SCHEMBL8352443 | 0.70 | TAAR1 (0.50) | OPRM1OPRD1TAAR1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL27428710 | 0.70 | KEAP1 (0.52) | OPRM1OPRD1TAAR1OPRK1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | BACE1, APP, BACE2 | OPRM1 3676/4885OPRD1 2074/4885TAAR1 2592/4885 |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | BACE1, APP, BACE2 | OPRM1 3676/4885OPRD1 2074/4885TAAR1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.